Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Substrate Specificity Discrimination and
2019-09-19
Substrate Specificity, Discrimination, and Binding Energy In iMDK mass to catalytic efficiency, which can be gauged in reference to an absolute scale of ‘catalytic perfection’ 10, 11, specificity is a relative concept because it requires comparison between given alternative substrates. In fact,
-
br Experimental Procedures br Acknowledgments We thank S Tan
2019-09-19
Experimental Procedures Acknowledgments We thank S. Tangye and A. Swarbrick for helpful discussions and critical reading of the manuscript; K. Wood, T. Camidge, and V. Turner for technical assistance; C. Brownlee for cell sorting; the staff of the Garvan Institute Biological Testing Facility f
-
With respect to the muscle compartment only
2019-09-19
With respect to the muscle compartment, only low protein expression of ASB9 has been detected in healthy human skeletal muscle [as reported in the Human Protein Atlas (HPA)], whereas high levels of Asb5 protein expression are detected in mammalian skeletal muscle, which appears to be important in th
-
The inhibition of mRFP Ub E formation by ginsenosides
2019-09-19
The inhibition of mRFP-Ub–E1 formation by ginsenosides Re was not in time-dependent in vitro (Fig. 4B). Fifty micrometres ginsenoside Rg1 decreased E1 activity to 0.24- to 0.36-fold over 30min. This finding suggests that ginsenoside Rg1 may irreversibly inhibit mRFP-Ub–E1 formation or a tight-bindin
-
Experimentally measured DGAT activity was first
2019-09-19
Experimentally measured DGAT activity was first reported by Weiss et al. (1960) and several different types of DGAT enzyme have since been described in plants [12,41,42]. As recently as 2011 there appeared to be just two DGAT enzymes both in plants and in other eukaryotes, namely DGAT1 and DGAT2 [43
-
Table shows the comparison results of error
2019-09-19
Table 2 shows the comparison results of error detection rate of each software-based CFC technique. Each version of benchmark is injected 10000 errors. Even though the injected errors are randomized in spite of their classifications, the large number of injected errors guarantees that all types of CF
-
WNV a member of the genus Flavivirus
2019-09-18
WNV, a member of the genus Flavivirus within the family Flaviviridae, was first isolated in 1937 from a febrile woman in the West Nile region of Uganda (Brinton, 2002). Until 1999, WNV was mainly confined to Southern Europe, the Middle East, Africa, West and Central Asia, Indonesia and Australia. In
-
The involvement of FOXO and STAT in DNA PKcs and
2019-09-18
The involvement of FOXO3 and STAT5 in DNA-PKcs and vasopressin receptor IV has not been reported before, and the search by the ECR browser (http://ecrbrowser.decode.org) revealed that 1kb of the 5′ promoter of DNA-PKcs possesses 4 STAT (−908bp to −901bp, −676bp to −656bp, −533bp to −526bp and −66bp
-
CAA is a carcinogenic metabolite of vinyl chloride forming s
2019-09-18
CAA is a carcinogenic metabolite of vinyl chloride, forming several different DNA adducts including the cyclic Scriptaid adducts 3,N4-ethenocytosine (εC), 1,N6-ethenoadenine (εA), N2,3-ethenoguanine (εG), and 1,N2-ethenoguanine (1,N2-εG), with the A and C cyclic adducts the most predominant, and al
-
A spectrum of therapies came in
2019-09-18
A spectrum of therapies came in order to counter this misfortune, some of them are discussed below. However, the common problem faced by most of these drugs is their emerging resistance after a span of time. Some of the important drugs reported so far are as: Quinine-based antimalarial drugs (Fig. 1
-
We hypothesized that the atopic phenotype
2019-09-18
We hypothesized that the atopic phenotype may be partially influenced by an altered binding and/or signalling due to the amino-acid substitution in the receptor protein. The principal aim of this study was to investigate the signalling mechanisms of the variants CysLT1-G300S and CysLT1-I206S induced
-
Based on the finding described above the present
2019-09-18
Based on the finding described above, the present study was designed to investigate the effects of specific CRF receptors, CRF1 and CRF2, in the BLA and CeA on the duration of TI in guinea pigs (Cavia porcellus). To this end, we evaluated whether administration of the CRF1 ana cas antagonist CP-376
-
The results showed that ethanol and acetaldehyde production
2019-09-18
The results showed that ethanol and acetaldehyde production was not affected by the presence of CPA-7. We observed that the concentration of ethanol increased throughout the assay up to 95–179 μL L-1 regardless of the treatment. The acetaldehyde concentration reached its highest values after 6–9 day
-
br Results and discussion br Conclusions
2019-09-18
Results and discussion Conclusions We have developed a method to produce wildtype and mutant Ric-8A proteins from E. coli that can be phosphorylated at the regulatory protein kinase CK2 phosphosites to near homogeneity. The phosphorylation status and activity of the purified Ric-8A proteins wa
-
br Methods br Results br Discussion There are
2019-09-18
Methods Results Discussion There are two particularly important facets of the present ERK findings relevant to drug conditioning. One is the strong ERK signal observed in the medial prefrontal cortex and the nucleus accumbens during the immediate post-trial interval following the final cond
15688 records 961/1046 page Previous Next First page 上5页 961962963964965 下5页 Last page